Preclinical Data on ARIAD's Novel Investigational mTOR Inhibitor, Deforolimus, to Be Presented at the AACR Annual Meeting
"In collaboration with our partner, Merck & Co., Inc., deforolimus is being studied in multiple cancer indications, both as a single agent and in combination with other therapies. Deforolimus has demonstrated positive results in Phase 2 clinical trials in patients with metastatic sarcomas and endometrial cancer and is currently being further studied in a Phase 3 clinical trial in patients with metastatic sarcomas," said Timothy P. Clackson, Ph.D., senior vice president and chief scientific officer of ARIAD.
The schedule and meeting place for the sessions, together with the abstract information, are listed below: -0-
Date & Time: Sunday, April 13, 2008, 1:00 p.m. to 5:00 p.m. Session Category: Experimental and Molecular Therapeutics 12 Session Title: Signal Transduction Abstract: #1482 Title: Anti-tumor activity of the mTOR inhibitor deforolimus (AP23573; MK-8669) in sarcoma and endometrial cancer models and exploration of molecular correlates of sensitivity Presenter: Rachel M. Squillace, Ph.D. Location: Exhibit Hall B-F; Poster Section 31 (Board 19)-0-
Date & Time: Tuesday, April 15, 2008, 8:00 a.m. to 12:00 p.m. Session Category: Experimental and Molecular Therapeutics 33 Session Title: Drug Discovery 2: Combination Strategies I Abstract: #4006 Title: Anti-proliferative activity of the mTOR inhibitor deforolimus (AP23573; MK-8669) in combination with cytotoxic and targeted agents in sarcoma and endometrial cancer models Presenter: Rachel M. Squillace, Ph.D. Location: Exhibit Hall B-F; Poster Section 29 (Board 4)
About ARIAD
ARIAD is engaged in the discovery and development of breakthrough medicines to treat cancer by regulating cell signaling with small molecules. ARIAD is developing a comprehensive approach to patients with cancer that addresses the greatest medical need - aggressive and advanced-stage cancers for which current treatments are inadequate. ARIAD has a global partnership with Merck & Co., Inc. to develop and commercialize deforolimus, ARIAD's lead cancer product candidate, which is in Phase 3 clinical development. ARIAD's second oncology product candidate, oral AP24534, is a novel multi-targeted kinase inhibitor in Phase 1 clinical development in hematological cancers. ARIAD has an exclusive license to pioneering technology and patents related to certain NF-(kappa)B treatment methods, and the discovery and development of drugs to regulate NF-(kappa)B cell-signaling activity, which may be useful in treating certain diseases. Additional information about ARIAD can be found on the web at http://www.ariad.com.
This press release contains "forward-looking statements," including statements related to ARIAD's oncology product candidates and commercial plans. Forward-looking statements are based on management's expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, the costs associated with our research, development, manufacturing and other activities, the conduct and results of pre-clinical and clinical studies of our product candidates, difficulties or delays in obtaining regulatory approvals to market products resulting from our development efforts, our reliance on our strategic partners and licensees and other key parties for the successful development, manufacturing and commercialization of products, the adequacy of our capital resources and the availability of additional funding, patent protection and third-party intellectual property claims relating to our and any partner's product candidates, the timing, scope, cost and outcome of legal and patent office proceedings concerning our NF-(kappa)B patent portfolio, the potential acquisition of or other strategic transaction regarding the minority stockholders' interests in our 80%-owned subsidiary, ARIAD Gene Therapeutics, Inc., future capital needs, risks related to key employees, markets, economic conditions, prices, reimbursement rates and competition, and other factors detailed in the Company's public filings with the U.S. Securities and Exchange Commission. The information contained in this press release is believed to be current as of the date of original issue. The Company does not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in the Company's expectations, except as required by law.
Contact
ARIAD Pharmaceuticals, Inc.
Edward M. Fitzgerald, 617-621-2345
or
Sheryl Seapy, 949-608-0841
Posted: April 2008
